DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, announced its participation in the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024, in New York City. The company's management will be available for one-on-one meetings throughout the event.
DiaMedica specializes in developing treatments for severe ischemic diseases, with their lead candidate DM199 being the first pharmaceutically active recombinant form of the KLK1 protein. This therapeutic approach is already established in Asia for treating acute ischemic stroke, preeclampsia, and other vascular diseases.
DiaMedica Therapeutics (Nasdaq: DMAC), una società biofarmaceutica in fase clinica, ha annunciato la sua partecipazione al 15° Annual Craig-Hallum Alpha Select Conference che si terrà il 19 novembre 2024 a New York. La direzione dell'azienda sarà disponibile per incontri one-on-one durante tutto l'evento.
DiaMedica si specializza nello sviluppo di trattamenti per gravi malattie ischemiche, con il suo candidato principale DM199 che rappresenta la prima forma ricombinante attiva farmaceuticamente della proteina KLK1. Questo approccio terapeutico è già consolidato in Asia per il trattamento dell'ictus ischemico acuto, della preeclampsia e di altre malattie vascolari.
DiaMedica Therapeutics (Nasdaq: DMAC), una compañía biofarmacéutica en etapa clínica, anunció su participación en la 15ª Conferencia Anual Craig-Hallum Alpha Select que se llevará a cabo el 19 de noviembre de 2024 en la ciudad de Nueva York. La dirección de la compañía estará disponible para reuniones individuales durante todo el evento.
DiaMedica se especializa en el desarrollo de tratamientos para enfermedades isquémicas severas, siendo su candidato principal DM199 la primera forma recombinante activa farmacéuticamente de la proteína KLK1. Este enfoque terapéutico ya está establecido en Asia para tratar el accidente cerebrovascular isquémico agudo, la preeclampsia y otras enfermedades vasculares.
DiaMedica Therapeutics (Nasdaq: DMAC), 임상 단계의 생명공학 회사는 2024년 11월 19일 뉴욕에서 열리는 제15회 Craig-Hallum Alpha Select Conference에 참여한다고 발표했습니다. 회사 경영진은 행사 기간 동안 1:1 미팅을 위해 참석할 예정입니다.
DiaMedica는 심각한 허혈성 질환 치료제 개발에 전문화되어 있으며, 주요 후보인 DM199는 KLK1 단백질의 첫 번째 약리학적으로 활성화된 재조합 형태입니다. 이 치료 접근법은 이미 아시아에서 급성 허혈성 뇌졸중, 자간전증 및 기타 혈관 질환 치료에 확립되어 있습니다.
DiaMedica Therapeutics (Nasdaq: DMAC), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à la 15e Conférence Annuelle Craig-Hallum Alpha Select qui se tiendra le 19 novembre 2024 à New York. La direction de l'entreprise sera disponible pour des réunions individuelles tout au long de l'événement.
DiaMedica se spécialise dans le développement de traitements pour des maladies ischémiques sévères, son candidat principal DM199 étant la première forme recombinante active pharmaceutiquement de la protéine KLK1. Cette approche thérapeutique est déjà établie en Asie pour traiter les AVC ischémiques aigus, la prééclampsie et d'autres maladies vasculaires.
DiaMedica Therapeutics (Nasdaq: DMAC), ein biopharmazeutisches Unternehmen in klinischer Phase, gab seine Teilnahme an der 15. jährlichen Craig-Hallum Alpha Select Conference bekannt, die am 19. November 2024 in New York City stattfinden wird. Das Management des Unternehmens wird während der gesamten Veranstaltung für persönliche Treffen zur Verfügung stehen.
DiaMedica ist auf die Entwicklung von Behandlungen für schwere ischämische Erkrankungen spezialisiert, wobei ihr Hauptkandidat DM199 die erste pharmazeutisch aktive rekombinante Form des KLK1-Proteins ist. Dieser therapeutische Ansatz ist bereits in Asien zur Behandlung von akutem ischämischem Schlaganfall, Präeklampsie und anderen Gefäßerkrankungen etabliert.
- None.
- None.
Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112148074/en/
Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Source: DiaMedica Therapeutics Inc.
FAQ
When is DiaMedica Therapeutics (DMAC) presenting at the Craig-Hallum Conference?
What is DiaMedica's (DMAC) lead drug candidate?
What diseases does DiaMedica Therapeutics (DMAC) focus on treating?
Where is DM199 already established as a therapeutic treatment?
